Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 16 ... other anticancer drugs. Xeloda is converted to the active cancer-killing agent 5-FU (5-fluorouracil) directly inside the cancer cells, thus reducing damage to healthy cells. Xeloda tablets ...
2009 NOV 20 ... results with a regimen of allopurinol and intralesional injections with a mixture of fluorouracil and low-dose triamcinolon." Wiest and colleagues published their study in ...
2009 NOV 23 ... According to recent research from the United States, "5-Fluorouracil (5-FU) is an antimetabolite that acts during the S phase of the cell cycle. The active ...
2009 NOV 16 ... lacking pRb and treated with systemic chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil) were disease free at a medium follow-up time of 109 months, whereas the clinical ...
2009 NOV 16 ... therapy were examined. Induction chemotherapy comprised cisplatin and 5-fluorouracil, and another cycle of chemotherapy was performed for responders. Chemoradiotherapy ...
2009 NOV 16 ... potential biomarker for treatment of HCC with sorafenib. The effects of sorafenib and 5-fluorouracil (5-FU) on cell proliferation were evaluated by cell viability assays in four HCC cell ...
2009 NOV 23 ... immune thrombocytopenia (OITP) during their tenth and seventeenth FOLFOX (5-fluorouracil/leucovorin/oxaliplatin) cycles. Herein, we report on a third patient who developed ...
2009 NOV 23 ... oxaliplatin-based combinations in these settings when compared with administration of 5-fluorouracil alone." "Pathologic evaluation of normal liver from patients undergoing ...
2009 NOV 16 ... received chemotherapy (physician's choice) plus bevacizumab [5 mg/kg every 2 weeks (5-fluorouracil regimens) or 7.5 mg/kg every 3 weeks (capecitabine regimens)]. The primary end point was ...
2009 NOV 9 ... and colleagues published their study in Annals of Oncology (Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line ...
2009 NOV 16 ... cell growth, and proliferation. Certain anticancer therapeutics, such as cisplatin and 5-fluorouracil, reportedly exert, at least partially, their activity through disruption of ribosome ...
2009 NOV 23 ... M. smegmatis UdgB also helps attenuate the cytotoxicity of the antimicrobial agent 5-fluorouracil." Wanner and colleagues published their study in the Journal of ...
2009 NOV 23 ... (1.8 Gy/d to a planned dose of 50.4-59.4 Gy), concurrent with two cycles of 5-fluorouracil (1000 mg/m(2)/d) and cisplatin (20 mg/m(2)/d), both given as 4-day continuous ...
2009 NOV 16 ... GAS1 suppression resulted in significant epirubicin resistance and cross-resistance to 5-fluorouracil and cisplatin in various gastric cancer cell lines. GAS1 suppression promoted multidrug ...
2009 NOV 16 ... of this association between both cellular pathways should advance the clinical use of 5-fluorouracil-based chemotherapy." Kong and colleagues published their study in ...
2009 NOV 16 ... but also induced apoptosis and enhanced sensitivity to chemotherapeutic drugs, 5-fluorouracil, and cisplatin. In addition, Bay11-7082 and sulfasalazine suppressed the migration and ...
2009 NOV 9 ... adjuvant chemotherapy for invasive breast cancer. The NCCN Guidelines now include FEC [fluorouracil (Adrucil®, Pfizer Inc.) / epirubicin (Ellence®, Pfizer Inc.) / ...
